Skip to main content

Advertisement

SpringerLink
Log in

Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Somatic mutations of KRAS, BRAF, HER2, PTEN genes are the most important molecular markers after the EGFR gene mutation. The current study evaluated the frequency and distribution pattern of KRAS, BRAF, HER2, PTEN mutation in Indian non-small cell lung carcinoma patients. The frequency of KRAS, BRAF, HER2, PTEN mutations was 6.4 % (14/204), 1.5 % (3/204), 1.5 % (3/204), 0 % (0/204), respectively. KRAS, BRAF, HER2 mutations were more prevalent in males than in females. KRAS and HER2 showed a trend of a higher frequency of mutation in the age group of <60 years, whereas BRAF mutations were more frequent in the age group of ≥60 years. Sequencing analysis of KRAS gene revealed c.34G>T (G12C) (n = 8), c.35G>A (G12D) (n = 3), c.35G>T (G12 V) (n = 1) and c.34G>T (G12C)/c.41T>C (V14A) (n = 2) mutations. Three different BRAF mutations (L584P: n = 1, V600E: n = 1, K601E: n = 1) were detected. Two cases harboured c.2324_2325ins12 (ATACGTGATGGC duplication) in HER2 gene, and one case was positive for NG_007503.2 (NM_001005862.2):c.2218-4del. It is less certain, but still quite possible that this mutation will affect splicing as the deletion of one C actually brings in one additional purine into the region. In conclusion, the present study demonstrates an instance of diverse nature of KRAS, BRAF, HER2 and PTEN gene in Indian patients and confirms that the frequency of these gene mutations varies globally. To the best of our knowledge, this is the first Indian study to evaluate KRAS, BRAF, HER2 and PTEN gene mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rath GK, Gandhi AK. National cancer control and registration program in India. Indian J Med Paediatr Oncol. 2014;35:288–90.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. 2013. http://globocan.iarc.fr. Accessed 14 April 2016.

  3. Behera D. Epidemiology of lung cancer—global and Indian perspective. J Indian Acad Clin Med. 2012;13:131–7.

    Google Scholar 

  4. Malik PS, Raina V. Lung cancer: prevalent trends and emerging concepts. Indian J Med Res. 2015;141:5–7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–80.

    Article  CAS  PubMed  Google Scholar 

  6. Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, et al. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. Breast J. 2013;19:149–55.

    Article  CAS  PubMed  Google Scholar 

  7. Vijayalakshmi R, Krishnamurthy A. Targetable, “driver” mutations in non small cell lung cancer. Indian J Surg Oncol. 2011;2:178–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. COSMIC 2005. Br J Cancer. 2006;94:318–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–72.

    Article  CAS  PubMed  Google Scholar 

  10. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012;104:228–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sánchez-Torres JM, Viteri S, Molina MA, Rosell R. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl lung cancer Res. 2013;2:244–50.

    PubMed  PubMed Central  Google Scholar 

  13. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574–9.

    Article  CAS  PubMed  Google Scholar 

  14. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046–51.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97:453–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10:25–38.

    Article  PubMed  Google Scholar 

  17. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74:139–44.

    Article  PubMed  Google Scholar 

  18. De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76:123–7.

    Article  PubMed  Google Scholar 

  19. De Greve J, Moran T, Graas M-P, Galdermans D, Vuylsteke P, Canon J-L, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31:8063.

    Google Scholar 

  20. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 2011;3:192–222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3 K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118:3762–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jin G, Kim MJ, Jeon H-S, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010;69:279–83.

    Article  PubMed  Google Scholar 

  23. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Das BR, Bhaumik S, Ahmad F, Mandsaurwala A, Satam H. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients. Pathol Oncol Res. 2015;21:675–87.

    Article  CAS  PubMed  Google Scholar 

  25. Liu Y, Liu B, Li X-Y, Li J-J, Qin H-F, Tang C-H, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res. 2011;30:111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–46.

    Article  CAS  PubMed  Google Scholar 

  27. Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, et al. Somatic mutation spectrum of non-small-cell lung cancer in African Americans: a pooled analysis. J Thorac Oncol. 2015;10:1430–6.

    Article  CAS  PubMed  Google Scholar 

  28. Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH, Ojopi EB. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics. 2012;67:419–24.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Chatziandreou I, Tsioli P, Sakellariou S, Mourkioti I, Giannopoulou I, Levidou G, et al. Comprehensive molecular analysis of NSCLC; Clinicopathological Associations. PLoS One. 2015;10:e0133859.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Dong YU, Ren W, Qi J, Jin BO, Li Y, Tao H, et al. EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Oncol Lett. 2016;11:2371–8.

    PubMed  PubMed Central  Google Scholar 

  31. Chen LF, Chen XY, Yu XB. Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi. 2016;45:221–5.

    CAS  PubMed  Google Scholar 

  32. Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, et al. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget. 2016;. doi:10.18632/oncotarget.8138.

    Google Scholar 

  33. Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K-I, et al. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surg Today. 2015. http://www.ncbi.nlm.nih.gov/pubmed/26711128. Accessed 20 May 2016.

  34. Li C, Hao L, Li Y, Wang S, Chen H, Zhang L, et al. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. PLoS One. 2014;9:e107276.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet. 2007;173:107–13.

    Article  CAS  PubMed  Google Scholar 

  36. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919–23.

    Article  CAS  PubMed  Google Scholar 

  37. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65:1642–6.

    Article  CAS  PubMed  Google Scholar 

  38. Nicoś M, Krawczyk P, Mlak R, Sawicki M, Jarosz B, Powrózek T, et al. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer—a potential application in classification for therapy. Pneumonol Alergol Pol. 2013;81:294–7.

    PubMed  Google Scholar 

  39. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431:525–6.

    Article  CAS  PubMed  Google Scholar 

  40. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997–2003.

    Article  PubMed  Google Scholar 

  41. Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MAC, Vidigal PV, Vilhena A, et al. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genet Res. 2014;96:e002.

    Google Scholar 

  42. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910–8.

    Article  CAS  PubMed  Google Scholar 

  43. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.

    Article  CAS  PubMed  Google Scholar 

  44. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012;2:791–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008;68:9375–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Authors are grateful to the management of SRL Ltd for providing the necessary infrastructure for the present research.

Author information

Authors and Affiliations

  1. Research and Development, SRL LTD, Plot No. 1, Prime Square Building, S.V. Road, Goregaon (W), Mumbai, 400062, India

    Sangeet Bhaumik, Firoz Ahmad & Bibhu Ranjan Das

Authors
  1. Sangeet Bhaumik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Firoz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bibhu Ranjan Das
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bibhu Ranjan Das.

Ethics declarations

Conflict of interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhaumik, S., Ahmad, F. & Das, B.R. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients. Med Oncol 33, 117 (2016). https://doi.org/10.1007/s12032-016-0828-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0828-7

Keywords

Search

Navigation